SARABJOT KAUR: Open Payments
NPI 1700282761 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$478 in 16 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $68 · 2025 $478
Food & beverage: $478
| Company | Payments | Amount |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | 1 | $143 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Novo Nordisk Inc | 3 | $58 |
| Alexion Pharmaceuticals, Inc. | 2 | $46 |
| ARGENX US, INC. | 1 | $33 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Boston Scientific Corporation | 1 | $23 |
| SK Life Science, Inc. | 1 | $22 |
| Indivior Inc. | 1 | $18 |
Products named: DAXXIFY, REXULTI, ULTOMIRIS, Ozempic, VYVGART, INGREZZA, CAPLYTA, WATCHMAN FLX.
Industry payments across IN — which companies pay providers there.
